The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Table 2 Association of sSIGLEC-1 with clinical parameters of SLE

Clinical parameter	Combined			EUR			Non-EUR
Clinical parameter	N (total)	OR^a (95% CI)	P value^b	N (total)	OR^a (95% CI)	P value^b	N (total)	OR^a (95% CI)	P value^b
Renal (nephritis)	156	1.53 (1.10–2.15)	0.01	75	1.65 (1.09–2.52)	0.02	81	1.16 (0.60–2.25)	0.67
Haematological	291	1.35 (0.95–1.92)	0.09	185	1.34 (0.80–2.20)	0.25	106	1.28 (0.72–2.25)	0.4
Biologics^c	35	1.20 (1.01–1.42)	0.04	23	1.18 (0.90–1.18)	0.19	12	0.95 (0.70–1.23)	0.71
Neurological	78	1.01 (0.76–1.34)	0.95	36	0.87 (0.63–1.18)	0.37	42	0.83 (0.39–1.76)	0.64
Admission	226	1.18 (0.81–1.71)	0.39	140	145 (0.90–2.37)	0.13	86	0.60 (0.30–1.21)	0.16
Corticosteroid use	302	0.98 (0.69–1.41)	0.96	174	0.96 (0.57–1.57)	0.86	128	0.88 (0.49–1.56)	0.35

Association of sSIGLEC-1 concentration with clinical parameters recorded from SLE patients occurring since their disease diagnosis and up to the time of their visit
CI confidence interval, EUR patients of European ancestry, non-EUR patients of non-European ancestry, SLE systemic lupus erythematosus, sSIGLEC-1 soluble sialic acid binding Ig-like lectin 1
^aOdds ratio (OR) calculated on the group of patients with sSIGLEC levels > 95th percentile
^bP values were calculated in each group using a logistical regression model, where the SLE patients were divided into groups based on sSIGLEC1 serum level centiles (< 50th centile, 51st–74th centile, 75th–95th centile and > 95th centile)
^cPatients treated with biologic drugs at the time of visit

ISSN: 1478-6362